LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma or the Company) announces that it will report its financial results for the first...
LONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma or the Company) announces that it will report its financial results for the fourth...
LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director. ...
LONDON and RALEIGH, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma or the Company), announces that senior management will present a company overview at...
Verona Pharma has inked a debt financing deal worth up to $400 million with Oxford Finance and Hercules Capital as it prepares for the potential approval and launch of its lead respiratory drug candidate.
Verona Pharma plc announces its President and CEO, David Zaccardelli, has won ˜Executive of the Year 2023' at the SCRIP awards.
LONDON and RALEIGH, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (œVerona Pharma or the œCompany), announces that senior management will present a company overview at...
US FDA accepted NDA filing for ensifentrine for maintenance treatment of COPD PDUFA Target Action Date of June 26, 2024 Commercial launch preparations supported by strong balance sheet Conference...
LONDON and RALEIGH, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (œVerona Pharma or the œCompany), a clinical-stage biopharmaceutical company focused on respiratory...
LONDON and RALEIGH, N.C., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (œVerona Pharma or the œCompany), announces it will hold an Investor Update in New York City for...